PARP inhibitor therapy is an effective treatment option for patients with metastatic pancreatic cancer and germline BRCA1/2 mutations.1 Identifying your patients with germline BRCA1/2 mutations is the first step to offering this new targeted therapy in your practice.
All Patients with Pancreatic Cancer Should
Receive Germline BRCA1/2 Testing at Diagnosis
- According to the NCCN Guidelines®, patients with pancreatic cancer should have genetic risk evaluation and BRCA 1/2 testing.2
- No family history is needed for patients with pancreatic cancer to meet genetic testing guidelines.
- Testing at diagnosis may identify patients who are eligible for olaparib maintenance treatment following first-line platinum-based chemotherapy.
Confidently Determine BRCA1/2 Status in One-week or Less for Pancreatic Patients
BRACAnalysis CDx was designed and FDA-approved to quickly provide accurate germline BRCA1/2 reports so you can confidently recommend the next treatment for your patient without delay.
BRACAnalysis CDx® has a priority option for patients with pancreatic cancer with a one-week turnaround time. Timing is critical to identify patients who are eligible for olaparib maintenance treatment following first-line platinum-based chemotherapy. Ordering BRACAnalysis CDx at diagnosis will provide you and your patients this critical information to determine if PARP inhibitor therapy is appropriate.
Accelerated Results for Patients
with Pancreatic Cancer
1. Place blood sample and completed test request form in the BRACAnalysis CDx Test Kit.
2. Place the priority label for patients with pancreatic cancer on the outside of the FedEx package.
Once Myriad receives the sample, you will receive the results of the BRACAnalysis CDx test in one week or less on your MyriadPro account. Reports will also be shipped overnight.
1 Golan et al. Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer. N Eng Jnl Med (2019).
2 Referenced with permission from the NCCN: Genetic/Familial High-Risk Assessment: Breast and Ovarian. Version 3.2019. ©National Comprehensive Cancer Network, Inc. 2018.